Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis
- Detailed Technology Description
- Project ID: D2013-62Invention Description and Novelty: Unique technology targets both ends of the bone remodeling process by introducing therapies to suppress osteoporosis and restore bone formation in the case of multiple myeloma and other cancer-induced bone diseases. Value proposition: · Unique injectable bone filler composition sets into a hardened mass comprised of a cement and other structures capable of releasing therapeutic agents or cells;· Composition exhibits mechanical and handling properties comparable to PMMA, and is osteoconductive, biodegradable, and less exothermic than PMMA;· Stabilizes fractured vertebrae and supports or induces bone regeneration;· Data shows that the method blocks bone resorption;· Provides reinforced cement scaffold, improving its handling properties and increasing its drug delivery capabilities;· Composition exhibits a synergistic effect to protect bone tissue from multiple myeloma or other disease-induced damage;· Therapeutic agents incorporated into the composition can also target myeloma cells to induce cell death or inhibit tumor progress, being administered directly to the location of the treatment instead of via circulation;· Suitable therapeutic agents for use in bone filler material include, but are not limited to: anti-osteoclastic agents, peptides, proteins, nucleic acids, antibiotics, antimicrobials, antifungals, antiseptics, antivirals, antiparasitics, antiprotozoals, wound healing agents, local anaesthetics, mucolytics, anti-allergies, antioxidants, vitamins, steroidal and non-steroidal anti-inflammatory agents, antihistamines, chemotherapeutic agents, tumor growth inhibitory agents, cytostatics, and combinations thereof.· Various additives may be included in the bone filler composition to adjust its properties;· Compositions and methods described herein could be embodied as parts of a kit or kitsApplications include but are not limited to bone augmentation surgery to treat cancer-induced bone disease.IP Status: PCT Patent Application No. PCT/US14/026,099
- *Abstract
-
- *Principal Investigator
-
Name: Vijay Goel, Professor
Department: Bioengineering
Name: Dong-Shik Kim, Asst. Professor
Department: Chem/Environmental Engr
Name: Sarit Bhaduri, Professor
Department: MIME
Name: Boren Lin, Research Associate
Department: BIOE
Name: Anand Agarwal, Research Professor
Department: Bioengineering
- Country/Region
- USA
For more information, please click Here

